Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial
Authors:
Open Access
- 4 June 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Abstract
Background: We conducted a quadruple-blinded, randomized, placebo-controlled trial of metformin for treating acute SARS-CoV-2 infection to prevent long COVID symptoms in low-risk adults. Methods: The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between 19 September 2023 and 1 May 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms were included within 7 days of symptom onset from 90 sites. Participants were randomized to metformin or placebo for 14 days. Postacute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician-diagnosed long COVID. Results: The median age was 47 years (interquartile range 38–57); 63% were female; 47% were Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or ≥2 SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The adjusted risk of symptoms on day 180 was 0.8 percentage points lower with metformin (95% credible interval [CrI] −2.2 to 0.6) with a posterior probability of efficacy (PPE) for preventing symptoms of 0.83, risk ratio 0.79 (95% CrI 0.474 to 1.230). Compared with placebo, the risk of clinician-diagnosed long COVID was 0.7 percentage points lower with metformin (95% CrI −1.5 to 0.1); PPE 0.96; risk ratio 0.495 (95% CrI 0.155–0.995). Conclusions: In low-risk adults, most with prior immunity, metformin did not exceed the efficacy threshold of 0.975 for PASC. Metformin reduced the risk of clinician-diagnosed long COVID. Clinical Trail Registration: ClinicalTrials.gov (NCT04885530).Keywords
Funding Information
- National Center for Advancing Translational Sciences (75A50122C00037)
- Biomedical Advanced Research and Development Authority
- Vanderbilt University Medical Center Clinical and Translational Science
This publication has 46 references indexed in Scilit:
- Metformin and Time to Sustained Recovery in Adults With COVID-19JAMA Internal Medicine, 2025
- Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs PlaceboJAMA Network Open, 2024
- Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 InfectionJAMA Internal Medicine, 2024
- Evidence Mounts That About 7% of US Adults Have Had Long COVIDJAMA, 2024
- Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19JAMA, 2023
- Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19JAMA, 2022
- Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 VeteransJournal of General Internal Medicine, 2022
- Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomesJournal of Thrombosis and Thrombolysis, 2022